Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function

Kidney International

Volumn 74, Issue 5, 2008, Pages 553-555

  Haslinger Löffler, Bettina ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MEVALONIC ACID; PRAVASTATIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; CHOLESTEROL BLOOD LEVEL; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL ANIMAL; HUMAN; IMMUNOMODULATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; NONHUMAN; NOTE; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY;

EID: 49749100814     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.323     Document Type: Note

References (10)

1. Kruger PS. Statins: the next anti-endotoxin. Crit Care Resusc 2006; 8: 223-226.
2. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: II18-II26.
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-321.
4. Sharyo S, Yokota-Ikeda N, Mori M et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008; 74: 577-584.
5. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
6. Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
7. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008; 61: 362-364.
8. Haslinger B, Goedde MF, Toet KH, Kooistra T. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int 2002; 62: 1611-1619.
9. Haslinger B, Kleemann R, Toet KH, Kooistra T. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int 2003; 63: 2065-2074.
10. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 1-43.